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Background: High Uric acid level has been found to be associated with 
hypertension; the aim of this study was to evaluate relationship between 
serum uric acid concentrations with blood pressure measurements in 
sudanese hypertensive patients living in khartoum state. 
Methods: Acase control study was carried out in Khartoum State; from 
march 2019 to july 2019. A total of 54 hypertensive patients were taken 
up for study that satisfied the inclusion and exclusion criteria. Similarly, 
54age and sex matched subjects were kept as control. Blood pressure and 
anthropometrics parameters were measured and serum uric acid level was 
evaluated using URICASE/POD/End point Essay. 
Results: This study demonstrated that there was significant association 
between uric acid level with both components of blood pressure systolic 
and diastolic. Furthermore, serum uric acid levels were significantly 
higher in non-elderly subjects (˂ 50 yrs) compared with elderly subjects 
(˃ 50 yrs) in hypertensive case. In addition, the result documented that 
there was significant association between uric acid level and duration of 
HTN.There was no significant difference in level of uric acid with BMI 
categories in case participants compare to control group. 
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Conclusion: In conclusion, This study demonstrated that there was 
significant association between uric acid level with both components of 
blood pressure systolic and diastolic. Furthermore, our data showed that 
serum uric acid levels were significantly higher in non-elderly subjects (˂ 
50 yrs) compared with elderly subjects (˃ 50 yrs) in hypertensive case. In 
addition, The result documented that there was significant association 























ٌُاك عالقت بيي حوغ اليْسيل ّ إسحفاع ػغؾ الذم. الِذف هي ُزٍ الذساعت ُْ حقيين العالقت    
بيي حشميض حوغ اليْسيل ّ قياعاث ػغؾ الذم عٌذ هشػى اسحفاع ػغؾ الذم. حوج ُزٍ 
 . 2019ّ حخى يْليْ  2019الذساعت في ّاليت الخشؽْم في الفخشة ها بيي هاسط 
شخظا هي هشػى إسحفاع ػغؾ الذم بعذ اعخيفائِن ششّؽ  ٤٥شاسك في ُزٍ الذساعَ عذد 
شخظا لِن ًفظ الخْاص العوشيت ّ  ٤٥الوشاسمت في ُزٍ الذساعت. ّ مزلل شاسك عذد أسبعت 
 غيش هظابيي بوشع إسحفاع ػغؾ الذم ّ ُن )عيٌت هقاسًت(.
اًج حن قياط ػغؾ الذم ّ قياعاث الْصى ّ الطْل ّ مخلت الجغن ّ حشميض حوغ اليْسيل ّ م
الٌخائج حٌض على أى ٌُاك عالقت ّاػحت بيي حشميض حوغ اليْسيل ّ إسحفاع ػغؾ الذم، ّ أى 
حشميض حوغ اليْسيل عالي عٌذ هي ُن أعواسُن دّى الخوغيي بالوقاسًت هع هي ُن أعواسُن 
فْق الخوغيي ّ رلل عٌذ هشػى إسحفاع ػغؾ الذم. ّ أيؼا حٌض الٌخائج على أى ٌُاك عالقت 
حوغ اليْسيل ّ الوذة الضهٌيت لإلطابت بئسحفاع ػغؾ الذم. ليظ ٌُاك فشق في  بيي حشميض
حشميض حوغ اليْسيل حبعا الخخالف هؤشش مخلت الجغن عٌذ هشػى إسحفاع ػغؾ الذم هقاسًت 
 بالعيٌت الوقاسًت.
الخالطت أى ٌُاك عالقت بيي حشميض حوغ اليْسيل ّ ػغؾ الذم ، ّ أى حشميض حوغ اليْسيل 
هي ُن دّى عي الخوغيي بالوقاسًت بوي ُن فْق عي الخوغيي هي هشػى إسحفاع اعلى في 
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Hypertension (HTN) in adults is the most common form of 
cardiovascular diseases. The prevalence of hypertension grows higher 
with aging, resulting in an increase in morbidity and mortality through 
various events such as myocardial infarction, heart failure, stroke, and 
renal failure (1-3). 
Hypertension is an important, increasing medical and public health 
problem. Worldwide prevalence estimates for hypertension may be as 
much as 1 billion individuals and approximately 7.1 million deaths per 
year may be attributable to hypertension (4). The world health 
organization( WHO ) reports that suboptimal blood pressure (>115 mm 
of Hg Systolic BP) is responsible for 62% of cerebrovascular disease and 
49% of ischemic heart disease(IHD). In addition, suboptimal blood 
pressure is the first attributable risk for death due to myocardial 
infarction, stroke, congestive heart failure, peripheral vascular disease 
and end stage renal disease throughout the world (4). Approximately 30% 
of adults are still unaware of their elevated blood pressure, more than 
40% of individuals are not on treatment, and two thirds of hypertensive 




Uric acid, which serves no biochemical function other than being an end 
product of purine metabolism, was first discovered in 1776. A Swedish 
chemist Scheele isolated it from a urinary tract stone. In 1797, a British 
chemist Wallaston detected uric acid in a tophus which was removed 
from his own ear. About 50 years later Alfred Baring Garrod, a British 
physician showed by chemical isolation that uric acid was abnormally 
high in gouty patients. In subsequent studies Garrod formulated a rational 
relationship between hyperuricemia and symptomatology of gouty 
patients (4).  
Hyperuricemia has been proposed to have an association with 
hypertension in various studies. Serum uric acid (UA) levels were 
demonstrated to be an independent predictor for developing hypertension 
(5,6,7). Regardless of the different ethnic origins, a continuous 
relationship between serum UA and blood pressure (BP) was observed in 
African-Americans and whites (8, 9) as well as in Asians (7, 10) 
including Koreans (11-13). For determining the causal role of serum UA 
in the development of hypertension, Mazzali et al. (14) demonstrated an 
elevation in serum UA followed by an increase in BP via a crystal-
independent mechanism in rat models. Reduction of serum UA was 
associated with a decrease in BP through the regulation of renin-
angiotensin and nitric oxide system. Therefore, the study aim to evaluate 
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serum uric acid levels in sudanese hypertensive  patients living in 




1.2.1 General objective: 
To study the serum uric acid levels in sudanese hypertensive patients 
living in khartoum state  . 
1.2.2 Specific objectives: 
 To determine the prevalence of hyperuricemia(Gout) in sudanese 
hypertensive patients. 
 To study the association of serum uric acid level to duration and 

















1.3 Review of literature: 
1.3.1 Hypertension: 
Hypertension or high blood pressure is a common condition in which the 
long term force of the blood against the artery wall is high enough that it 
may eventually cause health problems such as heart disease. 
Hypertension is the third leading killer disease in the world and is 
responsible for 1 in every 8 deaths. About 1 billion people are affected by 
hypertension worldwide . The prevalence of hypertension is known to 
increase with age. Over 50% of individuals aged 60 to 69 and over 75% 
of those aged 70 years and older are affected. Recent Framingham Heart 
Study reported that life time risk of developing hypertension is 
approximately 90% for men and women who are normotensive at 55-65 
years old and survived to the age of 80-85 years (15). 
Studies have shown that BP is an independent risk factor for 
cardiovascular disease(CVD). This relationship is independent, consistent 
and continuous. Observations involving more than 1 million individuals 
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have shown that death from both CVD and stroke increases progressively 
and linearly from BP levels of as low as 115mmHg systolic and 75 
mmHg diastolic upwards. The increased risks are present in all age 
groups ranging from 40 to 89 years old. For every increment of 20 mmHg 
systolic or 10 mmHg diastolic there was a doubling of mortality from 
both ischemic heart disease and stroke (16). 
Evidence also warrants greater attention to the importance of systolic 
blood pressure (SBP) as a major risk factor for CVD. The rise in SBP 
continues throughout life, in contrast to diastolic blood pressure (DBP), 
which rises until approximately 50 years age, tends to level off over the 
next decade, and may remain same or fall later in life. Clinical trials have 
demonstrated that control of isolated systolic hypertension reduces total 
mortality, cardiovascular (CV ) mortality and stroke (17,18). 
Blood pressure is determined both by the amount of blood pump by heart 
and the amount of resistance to blood flow in arteries. The more blood 
pumps by the heart, and the narrow arteries, the higher blood pressure. 
Normally blood pressure is 120 over 80 mmHg, but hypertension is 





1.3.1.1  Mechanism of hypertension: 
The roles of sodium and potassium in the pathogenesis of hypertension 
(19) appropriately emphasize the central roles of an excess of sodium, the 
expansion of extracellular fluid volume, the release of digitalis-like 
factor, a potassium deficit, and Na+/K+–ATPase inhibition. Digitalis-like 
factor is found mainly in the low renin, volume-expanded types of 
hypertension. A few clinical observations suggest that, in contrast to the 
effect of sodium chloride, blood pressure is not increased when sodium is 
consumed in the absence of chloride In stroke prone, spontaneously 
hypertensive rats, the rate of increase of blood pressure over time is 
specifically related to the chloride content of the diet. It seems 
appropriate to acknowledge the potential importance of the chloride ion 
in the pathogenesis of sodium-sensitive hypertension. However, from a 
clinical perspective, since most dietary sodium is ingested in the form of 
sodium chloride, it may be more practical to relate dietary 
recommendations specifically to sodium. Digitalis-like factor mediates 
sodium retention by increasing the activity and expression of the renal 
sodium pump. However, most studies have shown that ouabain and other 
digitalis-like steroids specifically inhibit the activity of the Na+/K+–




1.3.1.2 Pathologiccal consequences of hypertension: 
Many pathophysiologiccal factors have been implicated in the genesis of 
essential hypertension , increased sympathetic nervous system activity, 
perhaps related to heightened exposure or response to psychosocial stress; 
overproduction of sodium-retaining hormones and vasoconstrictors; long-
term high sodium intake; inadequate dietary intake of  potassium and 
calcium; increased or inappropriate renin secretion with resultant 
increased production of angiotensin II and aldosterone; deficiencies of 
vasodilators, such as prostacyclin, nitric oxide (NO), and the natriuretic 
peptides; alterations in expression of the kallikrein–kinin system that 
affect vascular tone and renal salt handling; abnormalities of resistance 
vessels, including selective lesions in the renal microvasculature; diabetes 
mellitus; insulin resistance; obesity; increased activity of vascular growth 
factors; alterations in adrenergic receptors that influence heart rate, 
inotropic properties of the heart, and vascular tone; and altered cellular 
ion transport . The structural and functional abnormalities in the 
vasculature, including endothelial dysfunction, increased oxidative stress, 
vascular remodeling, and decreased compliance, may antedate 
hypertension and contribute to its  pathogenesis has gained support in 
recent years. 
Although several factors clearly contribute to the pathogenesis and 
maintenance of blood pressure elevation, renal mechanisms probably play 
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a primary role, other mechanisms amplify (for example, sympathetic 
nervous system activity and vascular remodeling) or buffer (for example, 
increased natriuretic peptide or kallikrein–kinin expression) the pressor 
effects of renal salt and water retention. These interacting pathways play 
major roles in both increasing blood pressure and mediating related target 
organ damage (20). 
1.3.1.3 Classification of blood pressure: 
Based on the seventh report of the Joint National Committee on 
prevention, detection, evaluation and treatment of high blood pressure 
(JNC VII report) BP is classified into the following stages. 
Table: (1.1) classification of BP according to JNC VII Report: 
Classification of BP Systolic BP (mmHg) Diastolic BP (mmHg) 
Normal < 120 <80 
Prehypertension 120 - 139 80 - 89 
Stage 1 hypertension 140 - 159 90 - 99 
Stage 2 hypertension ≥160 ≥100 
In contrast with the classification provided in the JNC VI report, a new 
category designated prehypertension has been added and stages 2 and 3 
have been combined (20). 
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Patients with arterial hypertension and no definable cause are said to have 
Primary or essential or idiopathic hypertension. Individuals in whom a 
specific structural organ or gene defect is responsible for hypertension are 
defined as having a secondary form of hypertension (21). 
 Primary (essential) hypertension: For most adult; there is no 
identifiable cause of high blood pressure. This is type of high 
blood pressure called primary (essential) hypertension tend to 
develop gradually over many years. 
 Secondary hypertension: High blood pressure caused by 
underlying condition.  This is type of high blood pressure called 
secondary hypertension tend to appear suddenly and cause higher 
blood pressure than does primary hypertension. 
Various conditions lead to secondary hypertension: Obstructive sleep 
apnea, Kidney problems, Adrenal gland tumor, Thyroids problems, 
Medications such as contraceptive pills, cocaine and amphetamines. 
1.3.1.4 Accurate blood pressure measurement: 
Three sitting BP measurements at a 1 minute interval must performed 
according to current guidelines (cuff adjustment for arm’s circumference) 




1.3.1.5 Hypertension genetic considerations: 
Twin studies document greater concordance of blood pressures in 
monozygotic than dizygotic twins, and population studies show greater 
similarity in blood pressure within families than between families. 
Adoption studies demonstrate greater concordance of blood pressure 
among biological siblings than adoptive siblings living in the same 
household. Furthermore, single genes can have major effects on blood 
pressure, accounting for the rare Mendelian forms of high and low blood 
pressure. Mutations in 10 genes that cause Mendelian forms of human 
hypertension and 9 genes that cause hypotension have been described to 
date, as reviewed by Lifton and his colleagues. These mutations affect 
blood pressure by altering renal salt handling that the development of 
hypertension depends on genetically determined renal dysfunction with 
resultant salt and water retention. In most cases, hypertension results from 
a complex interaction of genetic, environmental, and demographic 
factors. Improved techniques of genetic analysis, especially genome-wide 
linkage analysis, have enabled a search forgenes that contribute to the 
development of primary hypertension in the population. Application of 
these techniques has found statistically significant linkage of blood 
pressure to several chromosomal regions; including regions linked to 
familial combined hyperlipidemia.These findings suggest that there are 
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many genetic loci, each with small effects on blood pressure in the 
general population. Overall, however, identifiable single gene causes of 
hypertension are uncommon, consistent with a multifactorial cause of 
primary hypertension.The candidate gene approach typically compares 
the prevalence of hypertension or the level of blood pressure among 
individuals of contrasting genotypes at candidate loci in pathways known 
to be involved in blood pressure regulation. The most promising findings 
of such studies related to genes of the renin–angiotensin–aldosterone 
system, such as the M235T variant in the angiotensinogengene, which has 
been associated with increased circulating angiotensinogen levels and 
blood pressure in manydistinct populations, and a common variant in the 
angiotensin-converting enzyme (ACE) gene that hasbeen associated in 
some studies with blood pressurevariation in men.The best studied 
monogenic cause of hypertension isthe Liddle syndrome, a rare but 
clinically important disorder in which constitutive activation of the 
epithelial sodium channel predisposes to severe, treatment-resistant 
hypertension. Epithelial sodium channel activation hasbeen traced to 
mutations in the subunits of thechannel, resulting in inappropriate sodium 
retention at therenal collecting duct level. Patients with the Liddle 
syndrome typically present with volume-dependent, lowrenin, and low-
aldosterone hypertension. Screenings ofgeneral hypertensive populations 
indicate that the Liddle syndrome is rare and does not contribute 
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substantially tothe development of hypertension in the general population 
(23). 
1.3.1.6 Hypertension symptoms and signs: 
Most people with high blood pressure have no sign or symptom even if 
blood pressure readings reach dangerously high level. Afew people with 
high blood pressure may have headache, shortness of breath, but these 
signs and symptoms are not specific and usually do not occur until high 
blood pressure has reach sever or life threatening stage. 
1.3.2 Association of hypertension with other conditions: 
1.3.2.1 Obesity: 
Hypertension is more common among obese individuals and adds to their 
increased risk of( IHD) especially if it is abdominal/visceral in location as 
a part of the metabolic syndrome. In the Framingham Study the incidence 
of hypertension was increased 46 % in men and 75 % in female who are 
overweight defined as a body mass index of 25.0 to 29.9 compared to 
normal weight persons (24). 
1.3.2.2 Physical Inactivity: 
People who are inactive tend to have higher heart rate. The higher heart 
rat, the harder heart must work with each contraction and the stronger the 
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force on arteries. Lack of physical activity also increases the risk of being 
over-weight (25). 
1.3.2.3 Alcohol Intake: 
Light to moderate alcohol consumption can decrease the risk of 
hypertension, whereas heavy alcohol intake is associated with an 
increased risk of hypertension. The association between alcohol 
consumption and hypertension may be changed by age (26). 
1.3.2.4 Smoking: 
A large number of observations identify cigarette smoke as a factor able 
to cause a functional and initially transient damage primarily of the 
endothelium and reduced tolerance to exercise stress testing because of 
the effects of nicotine and carbon monoxide. At the time, the functional 
damage became an irreversible pathological damage with ischemic 
lesions of the myocardium and artery vessel atherosclerosis. In its turn, 
hypertension plays harmful effects on the heart, kidney and arterial tree, 
mainly coronary, carotid and cerebral vascular structures, by its 






1.3.2.5 Sleep Apnea: 
Obstructive sleep apnea (OSA)is related to an increased risk of resistant 
hypertension. Mild, moderate and severe OSA is associated essential 
hypertension; as well a dose-response manner relationship is manifested. 
The associations are relatively stronger among Caucasians and male OSA 
patients (24). 
1.3.2.6 Hypercholesterolemia: 
Hyperlipidemia is twice as common in hypertensives in Africa compared 
to the general African population. Genderwise, hyperlipidemia was 
commoner among Hypertensives that are female (25). 
1.3.2.7  Hyperuricemia: 
The long-term effects of hypertension are well-known and in India is 
especially vulnerable to its impact. Since serum uric acid levels are 
strongly correlated with hypertension, evaluation of serum uric acid 
levels in patients at risk for hypertension and in those suffering from 
hypertension should be done as early as possible in the course of the 
disease. Treatment of hyperuricemia in hypertension with appropriate 





1.3.3 Uric acid metabolism: 
Uric acid is a heterocyclic compound of carbon, nitrogen, oxygen and 
hydrogen with formula C5H4N4O3. Uric acid is the final breakdown 
product of purine degradation in humans.Urates, the ionized forms of uric 
acid, predominate in plasma extracellular fluid and synovial fluid, with 
98% existing as monosodium urate at pH 7.4 (29). 
The pH of urine greatly influences the solubility of uric acid. Although 
purine nucleotides are synthesized and degraded in all tissues, urate is 
produced only in tissues that contain xanthine oxidase, primarily in the 
liver and small intestine. Urate production varies with the purine content 
of the diet and the rates of purine biosynthesis, degradation, and salvage. 
Normally, two-third to three-fourth of urate is excreted by the kidney, and 
most of the remainder is eliminated through the intestine. The kidneys 
clear urate from the plasma and maintain physiologic balance by utilizing 
specific organic anion transporters (OATs) including urate transporter 
1(URATI) and human uric acid transporter (hUAT). URAT1 and other 
OATs carry urate into the tubular cells from the apical side of the lumen. 
Once inside the cell, urate must pass to the basolateral side of the lumen 
in a process controlled by the voltage-dependent carrier hUAT. Until 
recently, component model has been used to describe the renal handling 
ofurate / uric acid.  
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URAT1 is a novel transporter expressed at the apical brush border of the 
proximal 
nephron. Uric acid compounds directly inhibit URAT1 on the apical side 
of the 
tubular cell (so-called cis-inhibition) (30). 
1.3.3.1 Hyperuricemia: 
The normal range for serum uric acid( SUA) levels was 2.40–5.70mg/dl 
in females and 3.40–7.00mg/dl in males respectively. Values above the 
upper limit were considered as hyperuricemia (31). 
1.3.3.2 Causes of Hyperuricemia: 
Hyperuricemia may be classified as primary or secondary depending on 
whether the cause is innate or is the result of an acquired disorder. 
However it is useful to classify hyperuricemia in relation to the 
underlying pathophysiology, i.e., whether it results from increased urate 
production, decreased excretion, or a combination of two.  
_Urate over production can be caused by idiopathic factor (primary), 
HPRT deficiency, PRPP synthetase overactivity, Hemolytic process, 
Lmphoproliferative diseases, Myeloproliferative diseases, Polycythemia 
vera, Psoriasis, Paget’s disease, Glycogenosis III, V, and VII, 
Rhabdomyolysis, Alcohol, Obesity. 
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_ Decreased Uric acid Excretion is either to be caused by Primary 
idiopathic, . Renal insufficiency,  Polycystic kidney disease, Diabetic 
insipidus, Hypertension, Acidosis. 
1.3.3.3 Classification of Hyperuricemia by Pathophysiology: 
Hyperuricemia can be classified into two types: 
(a) Primary or idiopathic hyperuricemia:  
The hyperuricemia is considered primary when it exists in the 
absence of coexisting diseases or drugs that alter uric acid 
production or excretion. It usually last lifelong. 
(b) Secondary hyperuricemia:  
This refers to excessive urate production (overproducer) or 
diminished renal clearance (under excretory) occurring as a 
consequence of another disease, drug and dietary product or toxin 
(32). 
1.3.3.4 Complications of hyperuricaemia: 
Cardiovascular disease:  
Hyperuricemia may increase risk factors for cardiovascular disease (33). 
Type 2 diabetes: 
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Hyperuricemia may be a consequence of insulin resistance in diabetes 
rather than in precursor. One study showed high serum uric acid was 
associated with higher risk of type 2 diabetes, independent of obesity, 
dyslipidemia and hypertension. Hyperuricemia is associated with 
components of metabolic syndrome, including in children. 
1.3.3.4.1 Uric acid stone formation: 
Kidneys stones can form through deposits of sodium urate microcrystals. 
Saturation levels of uric acid in blood may result in one form of kidney 
stones when the urate crystallizes in the kidney. These uric acid stones 
are radiolucent and so do not appear on an abdominal plain x-ray. Uric 
acid crystals can also promote the formation of calcium oxalate stones 
and acting as seed crystals.  
1.3.3.4.2 Gout: 
The most recognized complication of hyperuricemia is gouty arthritis. In 
the general population the prevalence of hyperuricemia ranges between 
2.0 and 13.2% and the prevalence of gout is between 1.3 and 3.7%. The 
higher the serum urate level, the more likely an individual is to develop 
gout. In one study, the incidence of gout was 4.9% for individuals with 
serum urate concentrations >540 umol/l (9.0 mg/dl) compared with 0.5% 
for those with values between 415 and 535 umol/l (7.0 and 8.9mg/dl). 
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The complications of gout correlate with both the duration and severity of 
hyperuricemia (34).. 
1.3.3.4.3 Hyperuricaemia and Renal System: 
Hyperuricemia also causes several renal problems: Nephrolithiasis, Urate 
nephropathy, a rare cause of renal insufficiency attributed to monosodium 
urate crystal deposition in the renal interstitium and Uric acid 
nephropathy, a reversible cause of acute renal failure resulting from 
deposition of large amounts of uric acid crystals in the renal collecting 
ducts, pelvis, and ureters (35). 
1.3.4 History of uric acid and hypertension: 
Hyperuricemia leads to the increase in BP values by stimulating oxidative 
stress and inflammatory mechanisms through endothelial dysfunction and 
proliferation of smooth muscle cells in the blood vessels and stimulation 
of the renin-angiotensin system (36). 
2. MATERIALS AND METHODS 
2.1 Study design:  
A case – control study 
2.2 Period of study:  
March to July 2019 
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203 Study area: 
Khartoum state capital of sudan, Alhuda private clinic. 
2.4 Study Population:  
54  hypertensive patients aged between 20-80 years were participated in 
this study from Khartoum state capital of sudan. 
54 normotensive healthy adults age between 20-80 years were served as 
control. 
2.5 Inclusion Criteria: 
 Age group between 20 to 80 years. 
 Both sexes were included. 
 Stage 1 and stage 2 Hypertension according to JNC-VII. 
2.6 Exclusion Criteria: 
 Hypertensive patients with target end organ damage 
a) Hypertensive Heart disease as evidenced by Left Ventricular 
hypertrophy on  electrocardiogram (ECG) voltage criteria / 
Hypertensive crisis / Malignant Hypertension. 
b) Hypertensive Nephropathy 
c) Hypertensive Retinopathy 
 Diabetes Mellitus – Type 1 and Type 2 or metabolic syndrome. 
 Patients with Chronic kidney disease. 
 Hypertensive Patients with known Cerebro-vascular disease. 
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 Hypertensive Patients with coronary Artery disease – Myocardial 
Ischemia orInfarction. 
 Patients with long term drug intake like steroids, Anti-Tuberculous 
Treatment (ATT), diuretics, antimetabolite or chemotherapy drugs. 
2.7 Sample size:  
A convenience sample of 108; 54 control and 54 cases 
2.8 Ethical consideration:  
The study was approved by the Ethical Committee of Faculty of 
Medicine, International University of Africa. 
2.9 Written formal Consent: 
The study groups identified by the above criteria (inclusion and 
exclusion) were first informed about the nature of the study. Participants 
willing for the study were selected after getting an informed and written 
consent from them. 
Thus, a total of 54 patients was taken up for study that satisfied the 
inclusion and exclusion criteria. Similarly, 54 age and sex matched 
subjects was kept as control. 
2.10 Data collection: 
Data was collected from participants using an anonymous standardized 
research tool (annex 1).  Socio-demographic data was collected and 
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include age, gender, ethnic group, and toxic habits such as smoking, 
tobacco and alcohol consumption.     
2.11 Blood pressure measurement method: 
Blood pressure was measured by using a mercury sphygmomanometer, 
properly sized blood cuff was wrap around the; and one inch above the 
antecubital fossa, the stethoscope's bell lightly pressed over the brachial 
artery just below the cuff's edge.  the cuff was  inflated rapidly  to180 
mmHg , the air released from the cuff at moderate rate; and observed 
sphygmomanometer while listening with stethoscope , the first knocking 
sound is the systolic pressure ,when the knocking disappears that is the 
diastolic blood pressure. 
2.12  Anthropometric measurements:  
2.12.1 Weight and height methods:                                              
Calibrated weight and height measure scale was used for weight 
measurement. Firstly the person was asked to remove any heavy clothes 
or items; then person's feet were set onto center of the scale platform with 
feet slightly a part for better balance, and ask person to look straight and 
then record the weight. For height measurement; the person  was  asked 
to remove his/her shoes prior to taking measurement; person was  be 
stand with his-her  feet slightly a part and back as straight as possible  
with the heels, shoulders should touch the surface of height board. Person 
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was asked to look straight ahead with head erect, the headpiece was 
placed flat against the wall at a right angle to the head, the headpiece was 
lowered until it firmly touches the crown of the head and the 
measurement was recorded.                                                  
2.1202 BMI: 
Body mass index (BMI) was calculated as weight kg/height squared 
(kg/m²) and subjects were considered as normal weight if their BMI was 
< 25 kg/m², overweight if their BMI from 25 to 29 kg/m² and obese if 
their BMI ≥ 30 kg/m². BMI = Wt/H2 kglm2. 
2.13 Sample collection: 
Five ml of venous blood was drawn from antecubital vein of patients in a 
plain vacutainer tube under sterile conditions after fulfilling the selection 
criteria. Serum separated by centrifugation at 3000 rpm for 15minutes 
and the separated serum  stored at -200 c for uric acid analysis. 
2.14 Uric acid measurement:  
Method: URICASE/POD, End point assay  
Principle:  
Uric acid is oxidized to Allantoin and hydrogen peroxide by the enzyme 
uricase. In the presence of peroxidase, released hydrogen peroxide is 
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coupled with aniline derivative and 4-amino antipyrine to form colored 
chromogen complex. Absorbance of colored dye is measured at 550nm 
and is proportional to the concentration of uric acid in the sample. 
 
Reagents: Table (2.1) 
 






Sample: Table (2.2) 
 
Assay Parameters:  
Mode ---------- End Point  
Wave Length ---- 550 nm  
Flow Cell temperature ---- 37°C  
Optical path length -------- 1 cm  
Blanking ------------ Reagent Blank  
Sample Volume ----- 20 µl  
Reagent Volume ---- 1000 µl  
Incubation time -------5 min  
Concentration of standard ----- 6mg/dl  
Stability of final colour ------- 15 min  
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Permissible Reagent Blank Absorbance ----- <0.4AU 
Linearity ------ 25mg/dl 
Units ---------- mg/dl 
Procedure: Table (2.3) 
  
Mixed well. Incubated at 37°C for 5 minutes. 
The analyzer was programmed as per assay parameters. 
1. The analyzer was blanked with reagent blank. 
2. Absorbance of standard followed by the test is measured. 
3. Results were calculated as per given calculation formula 
 
2.14 Statistical analysis:  
The Data was computerized through free downloadable software 
developed by the Centre of Disease Control, CDC/Atlanta, USA: Epi-info 
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7TM 7.5.1.2. The statistical packages for social sciences (SPSS version 
23) were used to clean, describe and analyse the data. Descriptive 
statistics to summarize count data graphically (frequency tables for 
estimation of prevalence and graphics) and numerically for continuous 
variables (mean, standard deviation, median). Statistical analysis was 
used ANOVA and t test to establish the relationship between 
hypertension and uric acid levels. All tests were considered as statistically 


















During the study period from march 2019 to July 2019 a total of 108 
participants were studied of which 54 patients were cases and 54 were 
controls who were participants without hypertension or any other 
condition known to cause raised serum uric acid levels. 
301 Age distribution of participants: 
Among the studied population, 78 participants fell in the age groups 
between 30 – 49 years of age. Only 30 of participants fell in the extreme 
ages of studied population. All the age groups in both cases and controls 
were matched well with subtle variations. Table (3.1) and Fig 1. 
Table (3.1) Age distribution of participants (N=108) 
Age groups  Cases  controls               
Total 
30 – 39 14 21                             35 
40 – 49   24 19                             43 
50 – 59 14 11                              
25 
60 – 69 




3                             5 





   
Figure (3.1). Age distribution of participants  
3.2 Gender distribution: 
Among the cases, total number of male patients was 37 and total number 
of female patients was 17. Among the controls, total number of male 
patients was 36 and total number of female patients was 18. Table (3.2), 
Fig 2. 
Table (3.2) Gender distribution of participants 
Gender  Male  Female  




































Figure (3.2). Gender distribution of participants 
3.3 Clinical characteristics of control participants:  
Table (3.3) shows the clinic characteristics of control participants. The 
mean of pulse rate was 72.8 ± 2.88 and mean of systolic blood pressure 
was 125 ± 1.99, mean of diastolic blood pressure was 80 ± 2.91, mean of 
respiratory rate was 18 ± 2.32 . 
Table (3.3) clinical characteristics of control participants 
 N  Minimum maximum Mean  Std. 
Deviation 
Pulse rate  54 68 79 72.8 2.88 
Systolic BP 54 120 130 125 1.99 
Diastolic BP 54 70 90 80 2.91 
Respiratory rate  54 15 23 18.18 2.32 
Temperature  54 36 38 36.43 0.72 






























3.4 Clinical characteristics of case participants: 
Table (3.4) shows clinic characteristics of case participants. The mean of 
pulse rate was 74 ± 2.33, the mean of systolic blood pressure was 153 ± 
5.52, the mean of diastolic blood pressure was 90 ± 4.45 and the mean of 
respiratory rate was 18.77 ± 3.21. 
Table (3.4) clinical characteristics of case participants 
 N  Minimum maximum Mean  Std. 
Deviation 
Pulse rate  54 67 80 74.66 2.33 
Systolic BP 54 120 180 153 5.52 
Diastolic BP 54 80 99 90 4.45 
Respiratory rate  54 13 32 18.77 3.21 
Temperature  54 36 38.5 36.64 0.55 
Uric acid levels 54 5.8 7.9 7.6 0.37 
      
 
3.5 Distribution of BMI for case participants: 
The results demonstrated that 9.3% of case participants were 
underweight, 16.7% were normal weight, 25.9 were overweight and 
48.1% were obese class I. table (4) fig 3. 
Table (3.5) Distribution of BMI for case participants 
BMI categories  Frequency  Percent (%) 
Under weight  5 9.3  
Normal weight  9 16.7 
Over weight   14 25.9 






Figure (3.3). Distribution of BMI for case participants 
3.6 History, clinical manifestations and habit:  
Table (3.6) shows history of post-diabetes mellitus and post-stroke in 
case participants and also shows family history of diabetes mellitus and 
stroke in case participants. In addition, table (3.6) shows clinical 
manifestation and habit of case participants. 
Table (3.6) History, clinical manifestation and habit 
Characteristics   Frequency  Percent (%) 
Post diabetes mellitus  6 11.1  
Post stroke  1 1.9 
Family history of diabetes mellitus  43 79.6 
Family history of stroke  24 44.4  
Pallor  9 16.7 
Clubbing  3 5.6 
Edema  18  33.3 
Xanthoma  4 7.4 
Tophi  10 18.5 
Arthritis  20 37  
Rhythm (abnormal) 3 5.7 
Character (abnormal) 18 33.9 
Vessel wall condition  35 64.8 
vegetable 13 24.5 
Non-vegetable 41 75.5 
Tobacco (snuff) 11 20.8 






















BMI categories  
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3.7 Duration of HTN Patients in case group: 
The duration of hypertension in case group was divided into three 
categories hypertensive those for duration of hypertension < 10, duration 
of hypertension 10 - 20 and duration of hypertension 21 - 31 years. The 
total number of patients with hypertension for duration of < 10 years was 
14 cases, the total number of cases with duration of hypertension 10 – 20 
years was 28 cases and the total number of cases with duration of 
hypertension 20 – 31 years was 12 cases. Figure 4. 
  
Figure (3.4). Duration of hypertension in case group 
3.8 Uric acid levels among age groups in case participants: 
The comparison of serum UA levels of hypertensive subjects in different 
age groups are presented in Figure( 305) Serum UA levels were 
significantly higher in subjects with hypertension among all the age 




















Duration of HTN (yrs) 
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uric acid levels were significantly higher in non-elderly subjects (˂ 50 
yrs) compared with elderly subjects (˃ 50 yrs) (P ˃ 0.05). 
 
Figure (3.5). Uric acid levels among age groups in case participants 
3.9 Uric acid levels among BMI categories in case group: 
The mean of uric acid level in underweight cases was 6.71 ± 0.11 mg/dl. 
The mean of uric acid level in normal weight cases was 6.67 ± 0.71 
mg/dl. The mean of uric acid level in overweight cases was 6.77 ± 0.57 
mg/dl. The mean of uric acid level in obese cases was 6.79 ± 0.28 mg/dl. 
The data analysis showed that there was no significant difference in the 











3.10 Comparison of components of blood pressure between case and 
control: 
The present study showed that the mean of systolic blood pressure among 
cases was 153 ± 13.5 mmHg and mean of diastolic blood pressure among 
cases was 90 ± 12.2 mmHg. 
Mean of systolic blood pressure among control was 126 ± 11.3 mmHg 
and mean of diastolic blood pressure among control was 80 ± 9.3 mmHg. 
There was significant rise in the components of blood pressure in case 
































Figure (3.7). Blood pressure components in case and control groups. **P 
˂ 0.003 vs. control group. 
3.11 Uric acid levels in case and control groups: 
The total numbers of cases were 54 (both male and female), the data 
analysis of the cases showed the mean uric acid level to be 7.6 ± 0.37 
mg/dl. 
The total numbers of controls were 54 (both male and female), the data 
analyzed showed a mean uric acid to be 4.48 ± 0.54 mg/dl. Our results 
demonstrated that there was significant rise in uric acid level in case 





Figure (3.8). Uric acid levels in case and control groups. **P ˂ 0.001 vs. 
control group. 
3.12 Number of cigarette per day in case group: 
The number of cigarette per day in case group was divided into four 
categories; 3 cigarettes per day, 4 cigarettes per day, 5 cigarettes per day 
and more than 6 cigarettes per day. The total number of patients take 3 
cigarettes per day was 4, take 4 cigarettes per day was 3 and these who 






Figure (3.9). Number of cigarette per day in case group. 
3.13 Smoking duration in case group : 
The smoking duration in case group was divided into two categories; less 
than 15 years and more than 15 years. The total number of patients with 
duration of smoking less than 15 years was 4 and the total number of 





































Figure (3.10). Smoking duration in case group. 
3.14 HTN duration and uric acid levels: 
The results showed that the mean of uric acid levels in patients with 
duration of HTN less than 10 years was 6.4 ± 0.32, the mean of uric acid 
levels in patients with duration of HTN 10 – 20 years was 6.9 ± 0.79 and 
the mean of uric acid levels in patients with duration of HTN more than 
20 years was 7.1 ± 0.63. there was significant decreased in the uric acid 
levels in patients with duration of HTN less than 10 years when compared 
































Figure (3.11). HTN duration and uric acid levels. 
**
P ˂ 0.031vs. 10 – 20 
years and 20 – 31 years. 
3.15 Correlation between components of blood pressure and uric acid 
levels: 
The data analysis demonstrated that there was significant positive 
correlation between uric acid levels and systolic blood pressure as well as 
diastolic blood pressure Sig. (2-tailed 0.000). table (3.7). 
 










Sig. (2-tailed  .000 .000 









Sig. (2-tailed .000  .000 
N  54 54 54 







Sig. (2-tailed .000 .000  
N 54 54 54 
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**. Correlation is significant at the 0.01 level (2-tailed). 
4. Discussion: 
The aim of the present study was to evaluate the relationship between 
serum uric acid level and hypertension. This study demonstrated that 
there was significant association between uric acid level with both 
components of blood pressure systolic and diastolic. Furthermore, The 
data showed that the serum uric acid levels were significantly higher in 
non-elderly subjects (˂ 50 yrs) compared with elderly subjects (˃ 50 yrs) 
in hypertensive case. In addition, The result documented that there was 
significant association between uric acid level and duration of HTN.There 
was no significant difference in level of uric acid in BMI categories in 
case participants. 
Although serum UA and BP showed a significant relation in the overall 
population, when we evaluated it according to different age groups (<40, 
40–59, ≥60), it was only significant in the non-elderly population under 
age 60 in both genders. There have been several studies suggesting that 
the strength of the relationship between serum UA and BP is more 
dominant in the younger age groups and decreases during the aging 
process as the duration of hypertension gets longer (1,5,11,,37). However, 
none of the previous studies have tried to investigate the effect of 
different age groups on the relation as a primary goal,This study is the 
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first study to confirm the effect of different age groups on the relation 
between serum UA and BP. 
The prognostic significance of serum UA in different disease entities such 
as diabetes, chronic kidney disease, and cardiovascular diseases have 
been recognized in several previous studies (4,8,,38). Understanding the 
relationship between each diseases and serum UA has been important due 
to the potential benefit which could be achieved by applying it to new 
treatment strategies. Feig et al. (22) mentioned that early hypertension 
developed in children and adolescents with hyperuricemia could be 
reversed with urate reduction. Considering the practical implications in 
every day clinical practice, The results suggest the same could be applied 
beyond the adolescent to the non-elderly adults under age 50 years with 
early hypertension and hyperuricemia. 
In the Current study, we found, a higher level of SUA among 
hypertensive patients compared with normotensive subjects; SUA levels 
were associated with the risk of hypertension. Furthermore, The result 
demonstrated that there was significant decreased in the uric acid levels 
in patients with duration of HTN less than 10 years when compared to 
other durations. This findings were consistent with other studies which 
reported that higher UA concentrations were independently associated 
with increased period of developing hypertension (39). Potential 
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mechanisms behind the link between hyperuricemia and the development 
of hypertension have included nitric oxide and renin-angiotensin 
aldosterone system pathways. UA could lead to endothelial cell 
dysfunction via nitric oxide synthetase and stimulate vascular smooth 
muscle cell proliferation (40). Furthermore, UA may also directly 
stimulate the renin-angiotensin aldosterone system (14). 
The data analysis showed that there was no significant difference in the 
level of uric acid in BMI categories. In contrast to this results ; Ying 
Duan et al. (41).demonstrated that a positive significant association 
between serum uric acid and obesity, especially in high serum uric acid 
level in overweight and obesity group. Similar result could be found in 
different studies (42,43) and the association was stronger in females than 
males in both overweight and obesity group. 
There are some limitations to this study. First, the data case-control, and, 
therefore, it is not possible to establish that relatively higher uric acid 
levels preceded or caused elevated blood pressure. Second, the sample 
size of this study was relatively small; therefore, the findings may not 
represent for the whole sudanese population. Finally, we did not have 
individual information on family history of hypertension and physical 




5. 1 Conclusion: 
In conclusion, This study demonstrated that there was significant 
association between uric acid level with both components of blood 
pressure systolic and diastolic. Furthermore, the data showed that the 
serum uric acid levels were significantly higher in non-elderly subjects (˂ 
50 yrs) compared with elderly subjects (˃ 50 yrs) in hypertensive case. In 
addition, the results documented that there was significant association 
between uric acid level and duration of HTN. 
502Recommendations: 
1/ Screenig for uric acid levels should be part of HTN workup 
investigations, for hypertensive and cardiovascular patients. 
2/ Excercise and BMI should be mudiraters. 
3/ Study the uric acid level and oxidative stress biomakers in obese 
subjects. 
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Sex : …………………………….. 












Past History : 
 Diabetes mellitus…………………. 
 / IHD……………………………… 
 / Stroke……………………………. 
Family History : 
 Diabetes mellitus…………………………. / 
 IHD………………………………….. 
 Stroke………………………………. 
Personal History : 
 Tobacco……yes| no 
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 - Smoking : Yes/No 
Quantity :……………………….. 
Duration :………………………. 
Alcohol Consumption : Yes/No 
Duration :……………………… 
Diet : Veg/Non-Veg 
Menstrual History :………………………… 














Condition of vessel wall:………. 
Other peripheral pulses:……….. 
BP (Sitting) : 1. mm Hg (Standing) : 1. mm Hg 
2. mm Hg. 2. mm Hg 
3. mm Hg 3. mm Hg 
Respiratory rate: /min Temperature : 0 F 
Height :………………….cms. 











We would to invite you to participate in a research study. You are free to participate 
and all information you will provide will be confidential and anonymous, 
Things you should know: 
 The purpose of this study is to measure the uric acid  levels in hypertensive 
patients . If you agree on participating we will ask some questions that will be 
confidential. 
 Your participation in this research will contribute to identify the risk factors 
related to your condition and will help in the management and prevention of 
the disease you are suffering from.   
 Your confidentiality will be ensured by the use of an anonymous research tool 
and the data will not be used for any other purpose rather than the research 
objectives. It is possible that other people may need to see the information we 
collected about you, these people work for the International University of 
Africa and State Ministry of Health that are responsible for making sure the 
research is done safely and properly. The study results will be published to 
arise national and international awareness of the public health problem of your 
disease and we ensure you that any information collected will not enable your 
direct identification. 
 Your right. It is totally up to you to decide to be in this study. Participation is 
voluntary. You will be given the privilege to answer only the questions you 
want and also to withdraw from the study at anytime you wish.  
 For any further question you may have about this research, feel free to 
contact any time 




By signing this document, you are agreeing to participate in this study. Make sure you 
understand what the study is about before you sign. If you have any question after you 
sign, you can contact the research team using the addresses provided above. 
 
I understand what the study is about and my questions have been satisfactorily 





Signature                                                               Date 
Annex (2) Consent: 
